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Aim: Coagulation and platelet function following out of hospital cardiac arrest (OHCA) at 1 
admission to a UK cardiology centre were investigated prospectively in this observational 2 
feasibility study, and compared to that of patients receiving percutaneous coronary 3 
intervention (PCI) for ST segment elevation myocardial infarction (STEMI).  4 
Method: Blood samples taken immediately  at emergency department admission from 5 
patients after  OHCA of probable cardiac origin were analysed using near-patient 6 
thromboelastometry and a platelet function analyser. . Physiological parameters, 7 
demographic information, bleeding rates and 30-day survival were recorded, and compared 8 
to that of patients undergoing PCI for STEMI. 9 
Results: Thirty patients were enrolled into each group. Platelet activation with thrombin 10 
receptor stimulation was reduced in OHCA patients compared to STEMI patients; mean TRAP 11 
AUC OHCA 79.3 (95% CI 63.7-94.9)  vs STEMI 101.6 (95% CI 87.4- 115.8), p=0.03. The 12 
maximum clot firmness time was prolonged in the OHCA group compared to the STEMI group; 13 
1718s (1545s – 1906s) vs 1544s (1387s – 1709s), p=0.01.  Other measures of clot formation 14 
and strength were comparable between groups. Hyperfibrinolysis (maximum lysis >=15%) 15 
was common in both groups (57% in STEMI; 50% in OHCA) but did not increase 30-day 16 
bleeding risk. 17 
Conclusion: OHCA patients demonstrated reduced thrombin receptor function at hospital 18 
admission but overall clot formation dynamics comparable to STEMI patients, indicating no 19 
gross coagulopathy post OHCA in our cohort. Hyperfibrinolysis was common both post OHCA 20 
and after STEMI.  The results of this small feasibility study cannot draw clinical conclusions 21 
but will inform power calculations for future studies. 22 
 23 
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1. Introduction	25 
Approximately 30,000 people receive cardiopulmonary resuscitation (CPR) in the United 26 
Kingdom (UK) every year following out of hospital cardiac arrest (OHCA)(1).  For those who 27 
have return of spontaneous circulation (ROSC), treating the underlying cause of cardiac arrest 28 
is central to their initial management. A common cause of cardiac arrest is acute coronary 29 
artery occlusion, most effectively treated with timely percutaneous coronary intervention 30 
(PCI)(2, 3).  31 
PCI consists of blood flow restoration and stent deployment, requiring judicious 32 
pharmacological platelet inhibition to prevent further thrombus formation within the stent. 33 
In this aspect post-OHCA care closely follows that for patients presenting with ST-segment 34 
elevation myocardial infarction (STEMI).  In the conscious patient, oral loading with 35 




effective platelet inhibition(4). OHCA patients are invariably unconscious so require a 1 
nasogastric tube for administration of crushed or dispersed drugs (which can be time 2 
consuming, may delay PCI and has an unknown pharmacological profile) or rectal 3 
administration. Alternatively, intravenous glycoprotein IIb/IIIa or P2Y12 inhibitors may be 4 
used, which are novel drugs largely untested in the OHCA population(5). At present, it is not 5 
clear whether post-OHCA platelet inhibition with the same drug strategy as is offered post 6 
STEMI is optimum(2).  7 
The complication of acute stent thrombosis is reportedly more common following OHCA than 8 
STEMI (10% and 2% respectively)(6, 7). It is not clear why this is the case but delays in drug 9 
administration due to logistical challenges discussed above, altered drug metabolism and/or 10 
inherent abnormalities of clotting and platelet function may be implicated. The risk of stent 11 
thrombosis must be balanced against excess bleeding rates, reported in up to 56% of 12 
Intensive Care Unit (ICU) admissions following cardiac arrest(8). Bleeding has been postulated 13 
to occur as a result of therapeutic cooling, unpredictable antiplatelet drug pharmacokinetics, 14 
and multiorgan failure in the days following cardiac arrest. 15 
Both stent thrombosis and bleeding complications can lead to excess morbidity and mortality. 16 
At present, we have little evidence upon which to balance the risks of bleeding and clotting 17 
in OHCA patients. As a first step, it would be valuable to understand what abnormalities of 18 
coagulation occur in the OHCA population prior to any drug administration.  19 
Cardiac arrest is the end point of a wide range of physiological insults, and so to pinpoint 20 
patients likely to have experienced OHCA as a result of coronary occlusion, an international 21 
consensus defined the “Utstein comparator” group(9). Utstein comparator patients have a 22 
witnessed OHCA likely due to a cardiac cause, and are in an initial arrest rhythm amenable to 23 
defibrillation. By recruiting this group, we aimed to identify a more homogenous population 24 
who are most likely to benefit from PCI. Patients undergoing PCI for STEMI offer the most 25 
comparable group to the Utstein comparator as they too have an acute coronary thrombus, 26 
without the systemic effects of cardiac arrest.  27 
We undertook a pilot observational cohort study to investigate whether a coagulopathy of 28 
cardiac arrest is apparent in Utstein comparator patients at admission to a single UK tertiary 29 
cardiology centre following OHCA.  30 
2. Methods	31 
The study was approved by the Wales REC 7 regional research ethics committee 32 
(16/WA/0161) and registered with ISRCTN (ISRCTN34122839). The study protocol has been 33 





Cardiac arrest group: Adult patients admitted at any time of day following OHCA who had 2 
sustained ROSC but remained comatose, met Utstein comparator criteria, and were deemed 3 
suitable for admission to ICU were eligible. The inclusion criteria were witnessed arrest; 4 
probable cardiac cause; initial arrest rhythm amenable to defibrillation. The exclusion criteria 5 
were non-cardiac cause for arrest apparent. 6 
Comparator group: Any adult brought to the cardiac catheter laboratory (CCL) with an acute 7 
STEMI for which they were offered PCI as primary treatment was eligible for recruitment.  8 
Patients known to be; pregnant, detained by Her Majesty’s Prison Service or under the Mental 9 
Capacity act, or lacking capacity prior to admission were not enrolled. 10 
Consent	and	ethical	considerations		11 
Due to the nature of the disease under investigation, OHCA patients deemed eligible were 12 
automatically enrolled into the study and a retrospective opinion was sought from a 13 
consultee. A personal consultee was a close family member, whilst a professional consultee 14 
(approached only if a personal consultee could not be identified) was the patient’s lead 15 
healthcare professional so long as they were not connected with the study. The consultee 16 
was asked to sign an assent form stating that they believed the patient would agree to 17 
continued enrolment. Patients were approached for retrospective consent once recovered 18 
and deemed to have regained capacity.  19 
The comparator group gave verbal assent prior to undergoing emergency PCI and 20 
subsequently signed a consent form within 48 hours of enrolment.  21 
Study	design	22 
This observational cohort feasibility study was undertaken at a single regional cardiology 23 
centre that covers a population of approximately 1 million in the South West of England,  24 
offering 24-hour PCI, supported by a 21 bedded general ICU.  25 
OHCA patients were admitted to the emergency department, assessed, stabilised and 26 
underwent clinical interventions (such as tracheal intubation, line insertions, computed 27 
tomography (CT) imaging, bedside echocardiogram) before being transferred to the CCL. 28 
Sedation with an infusion of Propofol, ventilation on an anaesthetic machine (Ohmeda Datex, 29 
Drager) and PCI were undertaken according to local practice.  STEMI patients were admitted 30 
directly into the CCL from the emergency medical services. The cardiology team assessed the 31 
patient, and gained consented for PCI treatment if deemed necessary.  32 
In both instances the clinical team were at liberty to deliver any drugs, including anticoagulant 33 
and antiplatelet drugs, and adjuncts they felt appropriate. Immediately following study 34 
enrolment two citrated blood samples were taken, alongside routine admission tests. OHCA 35 
patients’ samples were taken from peripheral venous puncture or a freshly placed arterial line 36 




drugs or anti-coagulation, and prior to commencement of formal temperature management. 1 
STEMI patients’ blood was drawn from the PCI arterial access sheath prior to administration 2 
of systemic anticoagulation. All STEMI patient had received aspirin by the time of arrival in 3 
the CCL. 4 
The ROTEM® delta analyser (Tem international, Munich) is a near-patient rotational 5 
thromboelastographic system for global assessment of coagulation function that enables 6 
direct measurement of the kinetics of clot formation, clot viscoelastic strength, clot lysis and 7 
the fibrinogen and components of clot formation. The test utilises three different activating 8 
reagents to assess the tissue factor (EXTEM reagent), or contact (INTEM reagent) mediated 9 
activation of coagulation. The fibrinogen component of clot formation is assessed using the 10 
FIBTEM reagent, which includes an inhibitor of platelet function. To assess platelet function, 11 
we employed the ROTEM® platelet system (Tem international, Munich), in which platelets are 12 
stimulated with activators of either the platelet thrombin receptor (TRAP reagent) or P2Y12 13 
ADP receptor (ADP reagent) and functional responses are measured by an electrical 14 
impedance endpoint. 15 
The ROTEM® viscoelastometry test generates several parameters: 16 
 Clotting Time (CT) indicates time in seconds from start of measurement until a clot with an 17 
amplitude of 2 mm forms, reflecting the time taken for soluble coagulation factors to initiate 18 
thrombin generation.  19 
Clot Formation Time (CFT) is the time taken for a 2mm clot to develop into a 20 mm one and 20 
reflects clot propagation which requires both platelets and coagulation factors.  21 
Maximum Clot Firmness (MCF) is the maximum amplitude of clot formed in millimetres. It 22 
represents the quality of the clot formed, reflecting contributions from both fibrinogen and 23 
platelets (EXTEM reagent) or fibrinogen alone (FIBTEM reagent).  24 
Maximum Lysis (ML) is the percentage of the clot lysed by the end of the reaction time 25 
expressed as a percentage of MCF and reflects fibrinolysis.  26 
MCF time and Lysis Onset Time report the time taken from the start of measurement to reach 27 
MCF and a 20% reduction in MCF respectively. 28 
The ROTEM® platelet generates three parameters for each activating reagent: 29 
Maximum speed (MS) is the maximum slope of the impedance versus time curve, reflecting 30 
rate of platelet aggregation.  31 
Amplitude at 6 minutes (A6) measures change in electrical impedance after six minutes 32 




Area Under the Curve (AUC) describes the area under the curve from the start of 1 
measurement to 6 minutes, reflecting overall platelet activation. 2 
Research staff were on call 24 hours a day during the study window to process samples.  3 
Samples were processed within 120 minutes of being drawn. All samples were analysed with 4 
the ROTEM® temperature set at 37˚C. Each ROTEM® test was run for 120 minutes.  5 
Data	collection		6 
The following data were collected; symptom onset time, , emergency service arrival time; 7 
arrival time in hospital; admission blood results; drug treatments given prior to and in the 8 
CCL; demographic data; past medical and drug histories. Patients were followed up for 30 9 
days for bleeding, return to CCL, and survival. 10 
Outcome	measures	and	data	analysis		11 
The primary aim of this study was to document platelet function in the OHCA patient 12 
population prior to administration of antiplatelet drugs. The secondary outcome was to 13 
document the coagulation function in this population.  14 
Conflicting data exists as to what coagulation and platelet derangement may be expected 15 
post OHCA(11-16), and therefore no a priori power calculation was undertaken. This study 16 
was intended to provide preliminary data to power future definitive studies. 17 
Prior to data analysis the ROTEM® and platelet traces were manually reviewed. Those with 18 
non-standard shaped traces were arbitrated by the authors (AS and AM). Results with evident 19 
artefact were manually analysed where possible, otherwise they were removed from the final 20 
dataset. In total 1 platelet ADP and 2 INTEM traces were discarded.  21 
Data were analysed using STATA (version 14.2, StataCorp, Texas). Where data was missing 22 
only the available numbers were analysed, no assumptions were made about missing data. 23 
Shapiro-Wilk tests for normality were carried out.  Parametric tests were used to analyse 24 
relationships between means and Chi2 or Fisher’s exact tests for categorical data depending 25 
on sample size. Mann-Whitney u tests were carried out on non-parametric data, and median 26 
difference was calculated using the Hodges-Lehmann Estimate. Logistic regression was used 27 
for binary outcomes. Significance was set at alpha = 0.05. Unless otherwise stated, all 28 
ROTEM® results refer to EXTEM reagent results. Reference ranges reported are those 29 
published by the ROTEM® manufacturer(17). 30 
3. Results	31 
Thirty patients were recruited into each study arm between September 2016 and May 2017 32 
(Figure 1). Three OHCA patients were excluded from analysis; 2 due to lack of consent, 1 due 33 
to insufficient blood samples. One  patient had data for platelet but not viscoelastometry 34 




The groups were well matched for age, gender and time parameters (Table 1). OHCA patients 1 
had a lower body temperature at the time of blood sampling;  35.2 ˚C (34.7 – 35.8) versus 2 
36.5 ˚C (36.4 – 36.7). OHCA patients were more often taking antiplatelet or anticoagulant 3 
medications pre-admission, more were hypertensive but fewer were smokers. Twenty-six of 4 
28OHCA patients received bystander CPR. Median time from collapse to sustained circulation 5 
was 22.5 minutes (range 4-63 minutes).   6 
Platelet	parameters	7 
The mean admission platelet count of OHCA patients was 256x109/L. No STEMI patient had a 8 
full blood count prior to PCI. The mean platelet count at the end of PCI was 235x109/L in OHCA 9 
patients and 251x109/L in STEMI patients. 10 
Platelet function tests (Table 2) demonstrate that mean TRAP AUC was lower in the OHCA 11 
arm (79.3, 95% CI 63.7-94.9) compared to the STEMI arm (101.6, 95% CI 87.4 – 115.8) p=0.03. 12 
Similarly, the A6 TRAP results were lower in the OHCA arm (18.0, 95% CI 14.4 – 21.6) than the 13 
STEMI arm (23.2, 95% CI 19.9 – 26.5), p=0.03.   14 
The platelet functional responses with the ADP reagent were similar in the two groups (Table 15 
2). 16 
The differences in TRAP response remained even when only P2Y12-antagonist naive patients 17 
were compared (OHCA TRAP AUC 75.0 (95% CI 59.9 – 90.2) versus STEMI TRAP AUC 101.6 18 
(95% CI 87.4 -115.8); mean difference of 26.5 (95% CI 6.2 – 46.8); p=0.01).  19 
Coagulation	parameters		20 
The absolute values of thromboelastometry are displayed in Tables 3, 6 and 7. A proportion 21 
of patients in both groups exhibited an EXTEM MCF above the reference range for healthy 22 
controls; 7/26 (27%) of OHCA patients, 7/29 (24%) of STEMI patients. No patients 23 
demonstrated an MCF below the lower limit, indicating adequate clot formation in both 24 
groups and no gross coagulopathy.   25 
The MCF time was prolonged in the OHCA patients at 1718s (95% CI 1545 – 1906) as compared 26 
to STEMI patients 1544s (95% CI 1387s – 1709s), p=0.01, suggesting that OHCA patients take 27 
significantly longer to reach maximal clot size (Table 3, Figs 12&13). 28 
There were no statistically significant differences between the groups in other 29 
viscoelastometry parameters (Tables 3,5,6). Aside from the MCF time, no other parameter 30 
exhibited clot formation dynamics outside of the reference ranges, indicating no 31 
hypercoagulability or severe coagulopathy in either group. 32 
Fibrinolysis		33 
Maximum lysis equal to or above 15% by the end of the 2-hour ROTEM® analysis, indicating 34 
hyperfibrinolysis, was demonstrated in 13/26 (50%) OHCA patients and 17/30 (57%) STEMI 35 




compared to OHCA patients without hyperfibrinolysis; 1595s  (1469 – 1739) vs 1906s (1665 – 1 
2147),  p<0.01. 2 
There were no differences in the other viscoelastometry parameters between OHCA patients 3 
with hyperfibrinolysis and those without (table 4).  One OHCA subject exhibited intermediate 4 
hyperfibrinolysis (complete clot lysis after 34 mins) and another late onset lysis (complete clot 5 
lysis after 108 mins) (18).   6 
30-day	outcomes		7 
In the OHCA group, 30-day survival was 15/28 (54%). The absolute 30-day bleeding rate was 8 
11/28 (39%) compared to 3/30 (10%) in STEMI patients, giving an odds ratio of bleeding of 9 
5.8 (95% CI 1.4 – 23.9, p=0.02). No coagulation differences were demonstrated between 10 
those OHCA patients who bled and those who did not, or between those who died and were 11 
alive at day 30 (Tables 7&8). 12 
Rates of stent thrombosis are difficult to quantify accurately in observational studies. Of the 13 
5 cardiogenic deaths in the OHCA arm, 1 was classified as a probable stent thrombosis by ARC 14 
criteria, giving a crude stent thrombosis incidence of 3.6% (1/28) (19, 20).  15 
4. Discussion		16 
In this feasibility study we have successfully recruited OHCA patients at emergency 17 
department admission for studies of coagulation and compared it to that of patients 18 
undergoing primary PCI for STEMI.  These groups were similar at baseline  despite their 19 
different routes of clinical presentation. Assessment of platelet function after OHCA with the 20 
novel ROTEM® platelet system showed reduced responsiveness to activation of thrombin 21 
receptors, as compared to STEMI patients. ADP receptor activity was comparable between 22 
the two patient populations, which goes against the findings of other groups(13, 16). Despite 23 
reduced thrombin receptor activity, maximum clot firmness was the same in both groups.  24 
Maximum clot firmness time was significantly prolonged in OHCA patients, corroborating the 25 
tendency of delayed clotting post OHCA(14). However, OHCA patients did eventually produce 26 
clots of the same firmness as STEMI patients indicating that no gross coagulopathy appears 27 
to exist, in contrast to some previous studies(11), but supporting others(21). The clotting time 28 
and clot formation time results show a trend to being prolonged, as had been demonstrated 29 
by other authors, suggesting this part of the coagulation pathway may be most sensitive to 30 
peri-arrest changes(12).  31 
Our rates of hyperfibrinolysis post OHCA are similar to other authors(12).  However, we found 32 
lower rates of fulminant, intermediate and late hyperfibrinolysis and no incidence of severe 33 
coagulopathy. OHCA patients exhibiting hyperfibrinolysis (ML ≥15%) had coagulation 34 
parameters comparable to the OHCA group as a whole (table 4), in keeping with the findings 35 




These findings suggest that OHCA patients tend towards slower clot formation, and some 1 
patients are also slower to lyse clots once they are formed (demonstrated by the wide 2 
interquartile range in lysis onset times in the OHCA group) (Table 3). This heterogeneity may 3 
explain why some OHCA patients are more prone to bleeding and others to clotting 4 
complications. To further assess whether this is the case, measurement of fibrin degradation 5 
products, thrombin and activated protein C or thrombomodulin will be helpful(11). 6 
Acute Traumatic Coagulopathy (ATC) has been more thoroughly investigated and we were 7 
interested to understand whether a similar process is occurring post OHCA. ATC is postulated 8 
to occur as a result of increased anticoagulant activity in the face of preserved procoagulant 9 
function, with increased fibrinolysis(22). Our data suggests that some patients show a similar 10 
picture; with hyperfibrinolysis and preserved MCF.  We did not demonstrate definitive 11 
increased anticoagulant activity. The pattern of increased fibrinolysis and preserved clot 12 
formation was demonstrated in both the STEMI and OHCA cohorts, and therefore does not 13 
seem unique to cardiac arrest.  Instead it may be a physiological response to a systemic insult 14 
and global hypoperfusion.  15 
 16 
Given the pragmatic design of this feasibility study there are a number of limitations.  17 
Although the difference in body temperatures between groups is not a confounder for 18 
analysis (as all samples were prewarmed and processed at 37˚C) it may nevertheless have 19 
implications for clinical management. Our sample size is small and we did not set out to show 20 
an effect on clinical outcomes.  21 
Due to the small sample size we have not undertaken multi-regression analyses of potential 22 
confounders. Limited staff availability meant that we were unable to recruit a consecutive 23 
sample. The grading of bleeding was not blinded. Body temperature on admission was 24 
collected retrospectively and was not available for all OHCA patients.  Clinical management 25 
was left to the discretion of clinicians, and variations may have influenced our results. 26 
This study was intended to provide proof-of-concept data to quantify the magnitude and 27 
direction of differences in coagulation and platelet function parameters between the two 28 
study populations. Given our small sample size, we were not expecting any differences to 29 
reach statistical significance. Nevertheless, we are confident that we now have an accurate 30 
representation of coagulation and platelet function on admission following a witnessed 31 
cardiac arrest in the Utstein comparator patient group. Future work will need to focus on 32 
elucidating the mechanism behind the altered platelet and fibrin system functions and 33 





We have demonstrated that Utstein comparator OHCA patients exhibited reduced thrombin 2 
receptor activated platelet function when compared to STEMI patients.  3 
ROTEM® coagulation analysis revealed admission clot formation dynamics tended towards 4 
prolonged clotting times post OHCA but with an ultimately normal, or increased, maximum 5 
clot firmness achieved. Over half of patients in both groups demonstrated hyperfibrinolysis.  6 
The small sample and hypothesis-generating nature of this work preclude any clinically 7 
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Fig 1 Recruitment flow diagram 
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OHCA (n=28) STEMI (n= 30)
Sex Male: Female (% Male) 20:8 (71%) 22:8 (73%)
Age 





Body temperature at time of blood sample




(36.4 – 36.7) 
Symptom onset to arrival in coronary catheter lab time 





Time from emergency call to hospital arrival 





Hospital arrival to coronary catheter lab time 




Time from symptom onset to antiplatelet loading 





Heparin administered in coronary catheter lab  (n, %) 16 (57) 29 (97)
Use of intravenous P2Y12 inhibitor Cangrelor® in coronary catheter lab (n, %) 15 (54) 1 (3)
Use of glycoprotein IIb/IIIa inhibitor in coronary catheter lab (n, %) 4 (14) 4 (13)
Received primary  PCI  (n, %) 18 (64) 26 (87)
Hypertension (n,( %)) 17(61) 7 (23)
Smoker (n,( %)) 3 (11) 8(27)
Diabetes mellitus(n,( %)) 6 (20) 6 (21)
Ischaemic heart disease (n,( %)) 3 (11) 2 (7)
Previous Myocardial infarction(n,( %)) 4 (14) 3 (10)
Pre-admission aspirin use(n,( %)) 7 (25) 2 (7)




a= data only 
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18 patients









Mean (95% confidence 
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Table 2. Platelet function parameters, comparing all STEMI and OHCA patients. AUC= area under the curve. MS =
maximum speed. A6 = amplitude at 6 minutes.
Parameter 

































































Table 3. median ROTEM® EXTEM coagulation parameters, comparing STEMI and OHCA patients
Parameter 
















(-30 – 3) 0.10
Clot Formation Time (s) 
(35-159)
79 




(-13 – 30) 0.49








( -10 – 4) 0.30







(-606 – -113) <0.01




(-27 – 49) 0.46
ADP AUC 53 (33 – 85)
36 
( 19 – 62)
15 
( -15 – 41) 0.41







(-15 – 11) 0.41
Incidence of bleeding by day
30 (n) 5/13 5/13 -
Hospital mortality (n) 4/13 8/13 0.12

























0 50 100 150 200
AUC TRAP












50 100 150 200
AUC TRAP




Fig. 4 Histogram of ADP AUC results for OHCA group (Shapiro-Wilk test for normality p=0.48) 
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Fig. 12 Histogram of Maximum Clot Firmness time in OHCA group (Shapiro-Wilk test for 
normality p=0.36)  
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Clotting Time (s) 
(100-240) 
184 










(52 – 98)  
66  
(56 – 72.5) 
10  






(60 – 72) 
66  
(63 – 70) 
-1  
(-5 – 3) 
0.66 
Maximum Clot 
Firmness time (s) 
1653 
 (1405 – 1942) 
1423  
(1296 – 1646) 
195  
(13 – 417) 
0.03 
Maximum lysis 
after MCF (%) 
(≤15%) 
12 
(8 – 15) 
13 
(11 – 14) 
-1  
































Clotting Time (s) 
 
63 
 (57 – 81) 
59 
 (56 – 62) 
2  






(80 – 425) 
815  
(90 – 1814) 
10  




(9 - 25) 
17  
(11 – 25) 
17.5  
(15 – 21) 
-1 
 (-5 – 3) 
0.99 
Maximum Clot 
Firmness time (s) 
1394.5  
(702 – 1841) 
1084  
(909 – 1417) 
195  
(13 – 417)  
0.29 
Maximum lysis 
after MCF (%) 
(≤15%) 
2  
(0 – 7) 
1  
(0 – 2) 
-1  















Table 7. Table comparing parameters of OHCA patients who bled versus those who did not 
bleed within 30 days post admission. (a = For ROTEM parameters  bled n=10 , not bled n=16) 
Parameter 
(reference range) 
OHCA patients who bled 
(n=11) 
Median (95% confidence 
interval) 
OHCA patients who did 
not bleed (n=16) 
Median (95% confidence 
interval) 
P value 





Downtime (mins) 25 
(20 – 44) 
21 





(2.7 – 6.7) 
2.6 





(42 – 120) 
76.5 





(19 – 85) 
52.5 
(31.5 – 67) 
0.66 
Clotting Time (s)a 
(38-79) 
70 
(66 – 78) 
67.5 
(62 – 86.5) 
0.38 
Clot Formation Time (s)a 
(35-159) 
66.5 
(51 – 98) 
76.5 
(54.5 – 89) 
0.96 




(60 – 75) 
65 
(63.5 – 73) 
0.85 
Maximum Clot Firmness 
time (s) a 
1702 
(1475 – 1802) 
1718 
(1570 – 1993) 
0.79 
Maximum lysis after MCF 
(%) (≤15%) a 
14 
(12 – 16) 
14.5 







Table 8. Table comparing parameters of those OHCA patients who were alive at 30 days 
versus those who had died. (a = For TRAP and ADP alive n= 14, died n= 13.  b = For ROTEM 
parameters alive n=14, died n=12). 
Parameter  
(reference range) 
OHCA patients alive at 




deceased at 30 days (n 
= 13)Median (95% 
confidence interval) 
P value 
Age (years) 57  
(48 – 69) 
72  
(66 – 79) 
<0.01 
Downtime (mins) 21.5  
(9 -33) 
23.0 





(1.1 – 6.7) 
2.8 





 (60 – 114) 
61  





(30.0 – 82.0) 
56.0  
(29.0 – 72.0) 
0.94 
Clotting Time (s)b 
(38-79) 
69.5 
 ( 66.0 – 100.0) 
68.0  
(62.0 - 74.5) 
0.47 




(75.5 – 87.0) 
77.0 






 (63.0 – 72.0) 
67.5  
(62.5 – 74.0) 
0.69 
Maximum Clot 
Firmness time (s)b 
1612.5  
(1485 – 1739) 
1850.5 
 (1718 – 2119) 
0.03 
Maximum lysis after 
MCF (%) (≤15%)b 
15.0  
(12.0 – 15.0) 
11.5 
 (5.5 – 21.5) 
0.30 
 
